Latest news for Foxtons Group (OTC:FXTGY) Stock

Foxtons Group PLC is an estate agency, providing residential property sales and lettings services in the United Kingdom. It operates in three segments: Sales, Lettings, and Financial Services. The sales segment generates a commission on sales of residential property. The letting segment earns fees from letting and management of residential properties and income from interest earned on tenant's deposits. The Financial Services segment generates commission from the arrangement of mortgages and related products under contracts with financial service providers and receives administration fees from clients. The majority of its revenue comes from the Letting segment.

News

Intraday Update

Markets

Movers

Trading Ideas

ABLZF

ACNFF

AFGC

AGESY

AGPPF

AGRO

AIMT

ALBY

ALCO

ALLE

ARGX

ARQL

ARRJF

ARVN

ASCC

ATAZF

ATBYF

ATLKY

AUPH

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

BBIO

BCUCY

BCVVF

BKFKF

BOCH

BOLD

BRBR

BRMK

BSDGY

BUKS

BXMT

BYAGF

BYDIF

CBSH

CGGYY

CGOOF

CHGCY

CMCXF

CODI

CRUS

CSIOY

CTBI

CUBA

DCPH

DFCO

DPMLF

EBMT

EFIN

EIDX

ESKYF

EXPR

FFBW

FLXN

FMNB

Cohen & Steers Closed-End Opportunity Fund

FRRVY

FSBW

FSUGY

FSUMF

FTSV

FXTGY

GBERY

GBNXF

GFED

GLPG

GMRE

GOSS

CERRO DE PASCO RES INC by Cerro De Pasco Res Inc.

GPPRF

GSAH

GSBD

Stocks That Hit 52-Week Highs On Tuesday

FOXTONS GROUP PLC ADR by Foxtons Group PLC

Foxtons Group PLC

JFBR

Jeffs' Brands announced that it has issued a non- recourse convertible promissory note in the principal amount of $2,850,000 to an institutional investor

WIIM

GE Vernova shares are trading lower after the company reported worse-than-expected Q4 EPS and revenue.

Telsey Advisory Group analyst Dana Telsey maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Market Perform and maintains $21 price target.

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on VF, Maintains $21 Price Target

Needham analyst Gil Blum initiates coverage on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy rating and announces Price Target of $9.

Initiation

ABSI

Needham Initiates Coverage On Absci with Buy Rating, Announces Price Target of $9

Guidance

Textron Sees FY25 Adj. EPS $6.00-$6.20 vs $6.42 Est.

Potter will also join the Company's Board of Directors. Potter will succeed Eric J. Lindberg, Jr., who has served as Interim President and Chief Executive Officer since October 2024.&nbsp;

Management

Grocery Outlet Holding Appoints Jason Potter As President And CEO, Effective February 3, 2025

Earnings

Earnings Misses

Textron Q4 2024 Adj. EPS $1.34, Inline, Sales $3.613B Miss $3.810B Estimate

Guidance:
GE Vernova is reaffirming its 2025 financial guidance of revenue of $36-$37 billion, high-single digits adjusted EBITDA margin&#x2A;, free cash flow&#x2A; of $2.0-$2.5 billion, and segment guidance of:&nbsp;
•Power: Mid-single digit organic revenue&#x2A; growth and 13%-14% segment EBITDA margin.
•Wind: Organic revenue&#x2A; down mid-single digits and $200-$400 million of segment EBITDA losses.
•Electrification: Mid-to-high-teens organic revenue&#x2A; growth and 11%-13% segment EBITDA margin.

GE Vernova Reaffirms FY25 Revenue Guidance Of $36B-$37B Vs. $36.88B Estimate

Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares are trading higher premarket on Wednesday.
On Tuesday, the company disclosed new AI agents and generative AI features in Oracle Fusion Cloud Sales to enhance sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43118973/oracle-ai-agents-help-sales-teams-create-more-meaningful-customer-connections" rel="noreferrer noopener">engagement and streamline processes</a>.
These AI capabilities, integrated with Oracle Fusion Cloud Customer Experience (CX), would help sales teams streamline communication, maintain up-to-date records, and build stronger customer relationships.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture" rel="noreferrer noopener">Nvidia, AI Stocks Rise As Trump Announces $500 Billion Stargate AI Infrastructure Venture</a>
The AI-powered engagement agent generates optimized emails, while the records agent automates activity summaries and data entry.
Rob Tarkoff, executive vice president and general manager, Oracle Cloud CX said, &#8220;The new AI agents and generative AI capabilities within Oracle Cloud Sales eliminate many of these rigid and time-consuming tasks, which enables sales teams to boost productivity and create more impactful connections with customers.&#8221;
Gartner predicts that by 2026, B2B sales teams using generative AI will cut prospecting and customer-meeting prep time by over 50%.
Yesterday, co-founder&nbsp;Larry Ellison unveiled plans for an artificial intelligence-driven cancer vaccine system <a target="_blank" href="https://www.benzinga.com/markets/equities/25/01/43118941/oracles-larry-ellison-says-cancer-vaccine-tailored-in-48-hours-could-soon-be-a-reality-as-trump-announces-500-billion-ai-investment" rel="noreferrer noopener">that could deliver personalized treatments within 48 hours</a>.
The announcement came as part of a broader $500 billion AI infrastructure initiative called Stargate, a joint venture between Oracle,&nbsp;OpenAI, and&nbsp;SoftBank Group. The project will&nbsp;establish massive data centers&nbsp;across the U.S., starting with a facility in Abilene, Texas.
Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and FT Vest Technology Dividend Target Income ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TDVI#BATS">TDVI</a>).
Price Action: ORCL shares are up 9% at $188.10 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43119814/google-parent-owned-startup-to-launch-ai-designed-drug-trials-by-year-end-partnering-with-eli-lilly-and-novartis-to-tackle-major-diseases" target="_blank" rel="noreferrer noopener">Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Tech

ORCL

TDVI

Oracle Unveils AI-Powered Sales Tools To Boost Customer Engagements: Details

Johnson & Johnson shares are trading higher after the company reported better-than-expected Q4 adjusted EPS and revenue.

Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) reported quarterly adjusted earnings of $1.20 per share which missed the analyst consensus estimate of $1.26 by 4.76 percent. This is a 17.81 percent decrease over earnings of $1.46 per share from the same period last year. The company reported quarterly sales of $825.00 million which missed the analyst consensus estimate of $837.57 million by 1.50 percent. This is a 5.50 percent increase over sales of $782.00 million the same period last year.

Comerica Q4 Adj $1.20 Misses $1.26 Estimate, Sales $825.00M Miss $837.57M Estimate

DELL

MSFT

NVDA

Shares of AI tech companies are trading higher after President Trump announced a $500 billion AI infrastructure investment called Project Stargate.

Stifel analyst James Condulis initiates coverage on Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announces Price Target of $80.

CYTK

Stifel Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $80

GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) reported quarterly earnings of $1.73 per share which missed the analyst consensus estimate of $2.55 by 32.16 percent. This is a 140.28 percent increase over earnings of $0.72 per share from the same period last year. The company reported quarterly sales of $10.59 billion which missed the analyst consensus estimate of $10.78 billion by 1.76 percent. This is a 8.51 percent increase over sales of $9.76 billion the same period last year.

GE Vernova Q4 2024 GAAP EPS $1.73 Misses $2.55 Estimate, Sales $10.59B Miss $10.78B Estimate

Full-year 2025 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in Billions, except EPS)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">January 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.0% – 3.0% / 2.5%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
</td>
</tr>
</tbody>
</table>
</figure>

Biotech

Health Care

General

Johnson & Johnson Expects 2025 Adjusted EPS Of $10.75–$10.95 Versus Consensus Of $10.59

William Blair analyst Max Smock downgrades Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) from Outperform to Market Perform.

Downgrades

William Blair Downgrades Charles River to Market Perform

Stifel analyst James Condulis initiates coverage on Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Hold rating and announces Price Target of $30.

EWTX

Stifel Initiates Coverage On Edgewise Therapeutics with Hold Rating, Announces Price Target of $30

NFLX

Netflix shares are trading higher following better-than-expected Q4 financial results. Multiple analysts raised their price targets following the report.

Johnson & Johnson Expects 2025 Sales Of $90.9B–$91.7B Versus Consensus Of $90.99B

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $2.01 by 1.49 percent. This is a 10.92 percent decrease over earnings of $2.29 per share from the same period last year. The company reported quarterly sales of $22.52 billion which beat the analyst consensus estimate of $22.44 billion by 0.37 percent. This is a 5.26 percent increase over sales of $21.39 billion the same period last year.

Johnson & Johnson Q4 2024 Adj EPS $2.04 Beats $2.01 Estimate, Sales $22.52B Beat $22.44B Estimate

Foxtons Group

Comments

Foxtons Group

News

Latest news for Foxtons Group (OTC:FXTGY) Stock

Tuesday, December 10, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga